...read the wave

Nano Biz...in depth... im detail


Arrowhead Research Corporation Acquires Early Nanosensor Patent Portfolio

PASADENA, Calif.--(BUSINESS WIRE)--May 19, 2005--Arrowhead Research Corporation (NASDAQ: ARWR - News ; NASDAQ: ARWRW - News ) announced today that it has acquired a suite of patent and patent applications covering nanosensor technology developed by Dr. Hermann Gaub, a Professor of Biophysics at the Center for Nanoscience at Ludwig-Maximilians University in Munich. Arrowhead and its subsidiaries now own or have licenses to over 250 U.S. and international patents and patent applications.

"Nanosensors are expected to radically change the way we diagnose disease. Now, we go to the doctor's office to have large samples of blood taken and then wait for days to get the results from a remote laboratory," said R. Bruce Stewart, President of Arrowhead. "With a nanosensor-enabled device, tests could be performed with a single drop of blood - and the results obtained within minutes."

The portfolio covers techniques for measuring biomolecular interactions by single-molecule force spectroscopy. As reported in "Science" in 2003, the devices are sensitive enough to detect single-base pair mismatches of DNA and have demonstrated significant improvement over state-of-the-art instrumentation. The patent applications also cover construction of parallel assays for placing millions of sensors on a chip. These patent and patent applications were acquired for a di minimus cash payment and are complementary to other patents to which Arrowhead already has rights.

About Arrowhead Research Corporation

Arrowhead Research is a nanotechnology company structured to bring together a diverse and innovative mix of technologies, rights to a broad suite of intellectual property, and some of the most respected minds in this dynamic field. There are three strategic components to Arrowhead's business model:

  • Forming or acquiring majority-owned subsidiaries engaged in the development and commercialization of nanoscale materials, devices, and systems.
  • Funding of prototype development at universities in exchange for the exclusive right to commercialize resulting intellectual property.
  • Acquisition, license and sublicense of intellectual property in the field of nanotechnology.

Arrowhead Research operates four majority-owned subsidiary companies:

  • Aonex Technologies, Inc. is developing and commercializing proprietary semiconductor nanomaterial technology.
  • Insert Therapeutics, Inc. is developing and commercializing proprietary nanometer-sized therapeutics.
  • Nanotechnica, Inc. is developing capabilities for mass-production of a variety of different, proprietary nanoscale devices and systems.
  • Calando, Inc. is developing nanostructures for delivery of RNA interference.

Arrowhead is also funding three research efforts in nanotechnology at Caltech in the areas of nanomaterials, nanoelectronics, and nanobiomolecular tools.

Contact: Arrowhead Research Corporation R. Bruce Stewart, 626-792-5549 bruce@arrowres.com

Source: Arrowhead Research Corporation

This story has been adapted from a news release -
Diese Meldung basiert auf einer Pressemitteilung -
Deze tekst is gebaseerd op een nieuwsbericht -


who is reading
the wave ?

missed some news ?
click on archive photo


or how about joining us


or contacting us ?


about us


our mission